ASAN, South Korea – A widely used gout medication may offer a new therapeutic approach for Gaucher disease, according to a recent laboratory study that identified colchicine as a promising candidate for drug repurposing. Researchers found that colchicine, an oral anti-inflammatory drug approved for gout and certain cardiovascular conditions, significantly...
Latest News
Amanda Judice was doing what many college students like to do on semester break – enjoying a winter ski trip. Then, her world turned upside down, and not from a tumble on the slopes. The 20-year-old product of Fatima and St. Thomas More, a Delta Delta Delta sorority member at...
Clinicohematologic complete response (CHCR) rates demonstrated that pegylated interferon alpha-2a was the most effective treatment for patients with essential thrombocythemia (ET), according to results of a real-world comparison with hydroxyurea and ruxolitinib in patients with myeloproliferative neoplasms (MPNs) reported in Hematology. The Philadelphia chromosome-negative MPNs (polycythemia vera [PV], ET, and myelofibrosis...
BOSTON – Compass Therapeutics, Inc. (OTC:CMPX) provided an update on the clinical development of CTX-009 (also known as ABL001), a dual anti-angiogenic bispecific antibody targeting DLL4 and VEGF-A. A Phase 2a study for CTX-009 in combination with paclitaxel was initiated by Handok Pharmaceuticals, Inc. (KOSDAQ: 002390) in Q1 2021 in...
At the start of the year, pharmacy benefit manager OptumRx predicted that 40% of all new FDA-approved products in 2020 would be orphan drugs. The PBM hasn’t changed that forecast, but it has come out with a bold new prediction about drugs that address small patient populations. Developers of orphan...
LEXINGTON, Mass. — Partner Therapeutics, Inc. (PTx) announced today the publication of a comprehensive review by Mora et al. in the International Journal of Cancer which summarizes the efficacy and safety of anti-GD2 monoclonal antibodies (mAbs) (dinutuximab, dinutuximab beta, and naxitamab) in children with high-risk neuroblastoma when given in combination with Leukine...
PHILADELPHIA, PA — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging...
OSLO, Norway – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces 21-month follow-up data from the randomized phase I/II trial of ONCOS-102 in combination with standard of care chemotherapy in malignant pleural mesothelioma (MPM). The trial is an open...
NORWOOD, Mass. — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) a clinical-stage company focusing on developing new therapies in oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) has cleared the start of the Company’s registrational study (“TEMPO-1”) of CRB-701, a next-generation Nectin-4...
Norwood, MA – Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company developing innovative medicines that target inflammation, fibrosis, metabolism and immuno-oncology, announced topline results from the Phase 3 DETERMINE study of lenabasum in adults with the rare, heterogeneous, autoimmune disease dermatomyositis. Primary endpoint: The study...